Amgen Planning PGx Study to Gain Full Regulatory Approval for Vectibix in US Market

The protocol for the trial, which will study overall survival in Vectibix-treated chemorefractory patients with wild-type KRAS tumors, is currently being reviewed by the FDA.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.